{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02081937",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CN301-XYK-CAR001"
      },
      "Organization": {
        "OrgFullName": "Chinese PLA General Hospital",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "CART-19 Immunotherapy in Mantle Cell Lymphoma",
      "OfficialTitle": "Anti-CD19 Chimeric Antigen Receptor Modified T Cells Infusion in Mantle Cell Lymphoma"
    },
    "StatusModule": {
      "StatusVerifiedDate": "March 2014",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 2014"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2018",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2019",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "March 6, 2014",
      "StudyFirstSubmitQCDate": "March 6, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "March 7, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "March 10, 2014",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "March 11, 2014",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Quanshun Wang",
        "ResponsiblePartyInvestigatorTitle": "Dr.",
        "ResponsiblePartyInvestigatorAffiliation": "Chinese PLA General Hospital"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Chinese PLA General Hospital",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Patients receive anti-CD19-CAR (coupled with CD137 and CD3 zeta signalling domains)vector-transduced autologous T cells over a period of 4 or 5 consecutive days in an escalating dose. After completion of study treatment, patients are followed intensively for 6 months, every 3 months for 2 years, and annually thereafter for 10 years.",
      "DetailedDescription": "PRIMARY OBJECTIVES:\n\nI. Determine the safety and efficacy of the chimeric antigen receptor T cells transduced with the anti-CD19 (cluster of differentiation antigen 19 ) vector (referred to as CART-19 cells) in elderly patients with MCL.\n\nII. Determine duration of in vivo survival of CART-19 cells. RT-PCR (reverse transcription polymerase chain reaction) analysis of whole blood will be used to detect and quantify survival of CART-19 TCR (T-cell receptor) zeta:CD137 and TCR zeta cells over time.\n\nSECONDARY OBJECTIVES:\n\nFor patients with detectable disease, measure anti-tumor response due to CART-19 cell infusions.\n\nEstimate relative trafficking of CART-19 cells to tumor in bone marrow and lymph nodes.\n\nDetermine if cellular or humoral host immunity develops against the murine anti-CD19, and assess correlation with loss of detectable CART-19 (loss of engraftment)."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Hematopoietic/Lymphoid Cancer",
          "Non-hodgkin Lymphoma,B Cell",
          "Mantle Cell Lymphoma"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "chimeric antigen receptor",
          "immunotherapy",
          "T lymphocyte",
          "mantle cell lymphoma"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "2",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Anti-CD19 CAR T cells",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Patients receive anti-CD19-CAR retroviral vector-transduced autologous or donor-derived T cells on d1-5 in the absence of disease progression or unacceptable toxicity.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: anti-CD19-CAR vector-transduced T cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "anti-CD19-CAR vector-transduced T cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Anti-CD19 CAR T cells"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Genetically engineered lymphocyte therapy"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Occurrence of study related adverse events",
            "PrimaryOutcomeDescription": "defined as >= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to the study.",
            "PrimaryOutcomeTimeFrame": "Until 2 years"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Clinical responses to CART-19 cell therapy",
            "SecondaryOutcomeTimeFrame": "Until 24 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMale and female with CD19+ relapsed or refractory MCL, and with no available curative treatment options (such as autologous or allogeneic SCT) who have limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled.\nNot eligible or appropriate for conventional allogeneic SCT\nPatients who achieve only a partial response to FCR(fludarabine, cyclophosphamide and Rituxan) as initial therapy will be eligible.\nBeyond 1st CR (complete remission) with relapsed or persistent disease and not eligible or appropriate for conventional allogeneic or autologous SCT\nDisease responding or stable after most recent therapy (chemotherapy, MoAb, etc...)\nRelapsed after prior autologous SCT\nResidual disease after primary therapy and not eligible for autologous SCT\nRelapsed after prior autologous SCT\nBeyond 1st CR with relapsed or persistent disease and not eligible or appropriate of conventional allogeneic or autologous SCT\nExpected survival > 12 weeks\nCreatinine < 2.5 mg/dl\nALT(alanine aminotransferase)/AST (aspartate aminotransferase)< 3x normal\nBilirubin < 2.0 mg/dl\nAny relapse after prior autologous SCT will make patient eligible regardless of other prior therapy\nAdequate venous access for apheresis, and no other contraindications for leukapheresis\nVoluntary informed consent is given\n\nExclusion Criteria:\n\nâ€¢ Pregnant or lactating women. The safety of this therapy on unborn children is not known. Female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion.\nUncontrolled active infection\nActive hepatitis B or hepatitis C infection\nConcurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary\nPreviously treatment with any gene therapy products\nFeasibility assessment during screening demonstrates < 30% transduction of target lymphocytes, or insufficient expansion (< 5-fold) in response to CD3/CD137 costimulation\nAny uncontrolled active medical disorder that would preclude participation as outlined\nHIV infection",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "50 Years",
      "MaximumAge": "80 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Quanshun Wang, Dr.",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "8610-66939486",
            "CentralContactEMail": "wqs63@sohu.com"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Department of Hematology of Chinese PLA General Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Beijing",
            "LocationState": "Beijing",
            "LocationZip": "100853",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Yu Zhao, Dr.",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "8610-55499304",
                  "LocationContactEMail": "zhaoyu301@126.com"
                },
                {
                  "LocationContactName": "Yu Zhao, Dr.",
                  "LocationContactRole": "Principal Investigator"
                },
                {
                  "LocationContactName": "Honghua Li, Dr.",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000008223",
            "ConditionMeshTerm": "Lymphoma"
          },
          {
            "ConditionMeshId": "D000020522",
            "ConditionMeshTerm": "Lymphoma, Mantle-Cell"
          },
          {
            "ConditionMeshId": "D000016393",
            "ConditionMeshTerm": "Lymphoma, B-Cell"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009370",
            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000008232",
            "ConditionAncestorTerm": "Lymphoproliferative Disorders"
          },
          {
            "ConditionAncestorId": "D000008206",
            "ConditionAncestorTerm": "Lymphatic Diseases"
          },
          {
            "ConditionAncestorId": "D000007160",
            "ConditionAncestorTerm": "Immunoproliferative Disorders"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          },
          {
            "ConditionAncestorId": "D000008228",
            "ConditionAncestorTerm": "Lymphoma, Non-Hodgkin"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10372",
            "ConditionBrowseLeafName": "Lymphoma",
            "ConditionBrowseLeafAsFound": "Lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M17980",
            "ConditionBrowseLeafName": "Lymphoma, B-Cell",
            "ConditionBrowseLeafAsFound": "Lymphoma, B-Cell",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21460",
            "ConditionBrowseLeafName": "Lymphoma, Mantle-Cell",
            "ConditionBrowseLeafAsFound": "Mantle cell lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11467",
            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10377",
            "ConditionBrowseLeafName": "Lymphoproliferative Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10355",
            "ConditionBrowseLeafName": "Lymphatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9358",
            "ConditionBrowseLeafName": "Immunoproliferative Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10374",
            "ConditionBrowseLeafName": "Lymphoma, Non-Hodgkin",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3543",
            "ConditionBrowseLeafName": "Lymphosarcoma",
            "ConditionBrowseLeafAsFound": "Lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T640",
            "ConditionBrowseLeafName": "B-cell Lymphoma",
            "ConditionBrowseLeafAsFound": "Lymphoma, B-Cell",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T3601",
            "ConditionBrowseLeafName": "Mantle Cell Lymphoma",
            "ConditionBrowseLeafAsFound": "Mantle cell lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}